A Feasibility Study for the Use of Multispectral Optoacoustic Tomography in the Detection of Tumors

Not Applicable

Completed

Conditions: Solid Tumor

Interventions: Device: MSOT Device
Procedure: Temperature Measurement

Registration Number: NCT04365413

Lead Sponsor: University of Oklahoma

Brief Summary: The purpose of this study is to evaluate the safety and potential of a new experimental imaging instrument called multispectral optoacoustic tomography (MSOT) to detect tumors and lymph nodes with tumors.

Detailed Description: This study will involve patients that are scheduled for routine standard of care surgery. It is a single-arm study designed to provide safety information regarding the use of the Acuity MSOT device in the clinical setting, and the ability of MSOT imaging data to correlate with clinical findings identified via pathology.

The device will be used to obtain images of the tumor or lymph node margins for investigational use only to compare to clinical pathology and patient's medical record. All images will be obtained pre- and post-surgery in a closed surgical patient. The temperature of the patient's skin will also be measured prior to and after MSOT imaging. MSOT imaging will be for research only and no treatment decisions will be based on the MSOT images obtained.

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 54

Inclusion Criteria

Patients with an identified solid tumor, i.e. breast (Stage I-IV), melanoma (Stage I-IV), HNSCC (Stage I-III), pancreatic (Stage I-III), ovarian (Stage I-IV) that is scheduled for surgical removal of the tumor and completed standard imaging prior to surgery
Have acceptable hematologic status [total hemoglobin (tHb) ≥ 10 mg/dL]
Patients ≥ 18 yrs of age
Patient provided a signed and dated informed consent
Willing to comply with study procedures and be available for the duration of the study
Ability to understand and the willingness to sign an IRB-approved informed consent document.

Exclusion Criteria

Patients with central nervous system tumors
Patients with a tattoo over the surgical site
Pregnant women
Women who are breastfeeding
Systemic or local infection
Any systemic anomaly during the pre-op assessment preventing patient participation in the study
Any febrile illness that precludes or delays participation preoperatively
Anything that would put the participant at increased risk or preclude compliance with the study
Patients with Stage IV pancreatic cancer, Stage IV HNSCC are not surgical candidates and therefore excluded from this study

Study & Design

Study Type: INTERVENTIONAL

Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Imaging of Tumor or Lymph node	MSOT Device	Tumors and/or lymph nodes of patients scheduled for standard of care surgery will be imaged using the MSOT device before and after surgery. The temperature of their skin prior to and after MSOT imaging will also be measured.
Imaging of Tumor or Lymph node	Temperature Measurement	Tumors and/or lymph nodes of patients scheduled for standard of care surgery will be imaged using the MSOT device before and after surgery. The temperature of their skin prior to and after MSOT imaging will also be measured.

Primary Outcome Measures

Name	Time	Method
Number of Participants With Adverse Events Due to MSOT Imaging	1-2 minutes	Adverse events as characterized by CTCAE v5.0 in patients that may result from MSOT imaging (≥44 degrees Celsius). Measurement of skin temperature pre- and post-MSOT imaging (2 measurements total) with a touch thermometer as part of the safety evaluation of the MSOT device. The thermometer will be placed onto the skin until a temperature appears, about 1 minute, and the temperature will be recorded.
Evaluate Skin Temperature Pre and Post Imaging (Pre- and Post- Surgery)	1-2 minutes after imaging	Percent of patients who experienced skin temperature readings \>44 degrees Celsius.

Secondary Outcome Measures

Name	Time	Method
Tumor Positivity From Pathology Reports Compared to MSOT Readings	6 months	Tumor positivity will be compared (yes/no) from the standard pathology report with the MSOT readings. Percent of patients with matching readings will be calculated and reported.
Tumor Positivity Based on Detection of Oxy-hemoglobin Using MSOT Device.	6 months	MSOT device can identify and differentiate between tumor tissue and surrounding tissue due to detection of different oxygenation states of hemoglobin, with the idea that tumors have differential tissue oxygenation levels compared to non-tumor (control) values. Tumor positivity will be determined based on comparison of oxy-hemoglobin levels using MSOT localization from the same size polygon region of interest (ROI) analysis of the tumor tissue and a sample of non-cancer tissue from the same patient. Increased intensity of signal (output obtained in MSOT Arbitrary Units (MSOT A.U.)) indicates higher levels of oxy-hemoglobin which correlates with tumor tissue as confirmed by comparison with pathology reports. Paired t-tests will be performed and median difference and IQR reported.
Tumor Positivity Based on Detection of Deoxy-hemoglobin Using MSOT	6 months	MSOT device can identify and differentiate between tumor tissue and surrounding tissue due to detection of different oxygenation states of hemoglobin, with the idea that tumors have differential tissue oxygenation levels compared to non-tumor (control) values. Tumor positivity will be determined based on comparison of deoxy-hemoglobin levels using MSOT localization from the same size polygon region of interest (ROI) analysis of the tumor tissue and a sample of non-cancer tissue from the same patient. Increased intensity of signal (output obtained in MSOT Arbitrary Units (MSOT A.U.)) indicates higher levels of deoxy-hemoglobin which correlates with tumor tissue as confirmed by comparison with pathology reports. Paired t-tests will be performed and median difference and IQR is reported.